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Monoclonal antibodies against the prototype 8FIIa strain of Norwalk virus were prepared and applied to an
enzyme immunoassay (EIA) for detecting Norwalk virus in stool specimens. The monoclonal antibodies
immunoprecipitated a 58-kDa protein which had been produced by in vitro transcription-translation of
Norwalk virus cloned cDNA, and they reacted by EIA with recombinant Norwalk virus capsid protein at a
sensitivity level of 1 ng/ml. The EIA detected virus in all tested samples from 15 different Norwalk virus-
infected volunteers. No cross-reactions were seen in stools containing other caliciviruses or in stools containing
rotaviruses, astroviruses, or enteric adenoviruses.
Norwalk virus, the prototype human calicivirus, is a major
cause of outbreaks of gastroenteritis, affecting primarily older
children and adults (1). Norwalk virus and other human cali-
civiruses have not been serially propagated in cell cultures,
which has inhibited the study of these viruses.
Diagnosis of Norwalk virus infections by serological means
or by antigen detection has relied for the most part on the use
of clinical materials obtained through human volunteer stud-
ies. Recent advances in the cloning of the Norwalk virus ge-
nome and the expression of Norwalk virus capsid protein (11,
12) have provided a simplified and reproducible means for
detection of Norwalk virus antibodies in serological studies.
Antisera to recombinant Norwalk virus (rNV) capsid protein
have also been prepared and used in an enzyme-linked immu-
nosorbent assay (ELISA) for antigen detection. The ELISA
used was highly specific for Norwalk virus and showed that
some virus isolates that had been previously identified as Nor-
walk-related viruses by tests using human reagents were dis-
tinct from the prototype Norwalk virus (5). In this report we
describe the development of monoclonal antibodies to stool-
derived Norwalk virus and their reactivities with clinical stool
samples from Norwalk virus-infected volunteers, with rNV
capsid protein, and with Norwalk virus protein expressed by in
vitro transcription-translation.
Norwalk virus was obtained from the diarrheal stool of a
volunteer who had been inoculated with Norwalk virus strain
8FIIa. Virus was partially purified from stool material by dif-
ferential centrifugation and banding in CsCl gradients, essen-
tially by the procedures described by Greenberg et al. (7).
Fractions were collected, assayed for density, and tested by
ELISA for Norwalk virus antigen. Fractions which had densi-
ties of 1.34 to 1.40 g/ml and showed high-level reactivity by
ELISA (described below) were pooled, dialyzed against 0.01 M
phosphate-buffered saline (pH 7.2), and used as the virus in-
oculum for hybridoma production. Stools containing Norwalk
virus antigen obtained from other volunteers were used for
screening hybridomas.
Stool samples containing other viruses were used for speci-
ficity testing of the monoclonal antibodies obtained. These
samples included stools containing various United Kingdom
strains of human calicivirus (3), samples containing astrovi-
ruses, enteric adenoviruses, rotaviruses, Hawaii virus, Snow
Mountain virus, unclassified ‘‘small round’’ viruses, and addi-
tional samples from Norwalk virus-infected volunteers (8–10).
For hybridoma production, BALB/c mice (8-week-old fe-
males) were inoculated subcutaneously with 0.1 ml of stool-
derived Norwalk virus emulsified in an equal volume of Titer-
Max adjuvant (Vaxcel, Inc., Norcross, Ga.). The mice were
given a second subcutaneous inoculation 3 weeks later. The
mice were given two more inoculations (intraperitoneally) of
Norwalk virus in Freund’s incomplete adjuvant and one intra-
peritoneal inoculation of virus without adjuvant, all 2 weeks
apart. Five days after the last inoculation, mouse spleens were
fused to SP 2/0 myeloma cells with Kodak polyethylene glycol
1450 plus dimethyl sulfoxide, according to the procedures de-
scribed by Lane (13). Hybrid cells were seeded onto 24-well
plates in hypoxanthine-aminopterin-thymidine medium con-
taining 10% Hybridoma Cloning Factor (IGEN, Inc., Rock-
ville, Md.). After 7 days, hybridomas were screened for anti-
bodies which reacted with Norwalk virus antigen. Hybridomas
that secreted such antibodies were cloned twice by use of the
limiting dilution technique. Ascitic fluids for all clones were
prepared in BALB/c mice.
Enzyme immunoassays (EIAs) were used for screening hy-
bridoma supernatant fluids and for testing virus-specific reac-
tivity. For these tests, both stool extracts known to contain
Norwalk virus antigen and rNV capsid protein were tested by
a modification of an EIA which used polyclonal human sera for
detection of Norwalk virus (9). For the indirect EIA used to
screen hybridomas, wells of polyvinyl chloride microtiter plates
were coated with pre- and postchallenge sera (4-week conva-
lescent phase) from a volunteer infected with Norwalk virus.
The wells were coated for 24 h at room temperature (20 to
228C) and postcoated with 1% (wt/vol) bovine serum albumin
in 0.01 M phosphate-buffered saline (PBS) for 24 h at 48C.
Suspensions of stool-derived Norwalk virus or rNV capsid pro-
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tein were added to the wells and incubated for 18 to 24 h at 20
to 228C. The plates were washed with PBS, and 0.05-ml por-
tions of hybridoma supernatant fluids diluted in 50% fetal calf
serum–50% 0.025 M Tris-HCl buffer (pH 7.2) with 0.015%
Tween 20 were added and incubated for 1 h at 378C. Peroxi-
dase-labeled goat antibody specific for mouse immunoglobulin
G (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Md.),
at 1 mg/ml in the Tris buffer described above, was added and
incubated for 1 h at 378C. The plates were washed five times
with PBS, soaked for 30 s with PBS containing 0.05% Tween
20, and washed again. Substrate for peroxidase (0.05 ml of
o-phenylenediamine-H2O2; Abbott Laboratories, North Chi-
cago, Ill.) was added and left for 10 min, and the reaction was
stopped with 0.1 ml of 1 N H2SO4. The A492 of the solution was
measured in a plate-reader spectrophotometer. After mono-
clonal antibodies were obtained, a direct EIA was used for
testing stool samples. The same monoclonal antibodies were
used for coating plates and for antigen detection. The antibod-
ies were purified from ascitic fluid by ammonium sulfate pre-
cipitation and either used directly for coating plates or labeled
with peroxidase for use as detector antibodies. The antibodies
were labeled with peroxidase by the periodate method of Wil-
son and Nakane (15). For the EIA, wells were coated with
monoclonal antibodies (2 mg/ml) for 18 to 24 h at 20 to 228C,
washed, and postcoated with Superblock (Pierce Chemical
Co., Rockford, Ill.) for 4 to 6 h. The plates were washed, and
stool samples or controls (known positive and negative stool
samples) were added and incubated for 18 h at 20 to 228C. The
plates were washed, and the peroxidase-conjugated antibodies
were added and incubated at 378C for 2 h. The remaining
procedures were as described for the indirect EIA. Samples
were considered positive for monoclonal antibody to Norwalk
virus in the screening tests, or for Norwalk virus antigen in the
virus specificity tests, if the absorbance value was both $0.1
and three or more times that of the negative control (wells
coated with preimmune serum in the screening tests and wells
coated with an unrelated monoclonal antibody in the virus
specificity tests).
Radioimmunoprecipitation tests were done to determine
the reactivities of the monoclonal antibodies with Norwalk
virus capsid proteins produced in vitro. These proteins were
produced from full-length open reading frame (ORF)-2
clones, which are known to code for the Norwalk virus capsid
protein (12). Reverse transcriptase-PCR was used to obtain
full-length ORF-2 clones from Norwalk virus RNA isolated by
silica extraction (2, 6) from a fecal sample containing intact
virus particles. Oligo(dT) was used for reverse transcription to
produce first-strand cDNA. Specific Norwalk virus primers
were used in first-round PCRs. PCR products were amplified
by using a ‘‘half-nested’’ approach (same 59-end primers as in
the first round, with a unique 39-end primer internal to the
first-round 39-end primer). Second-round PCR products were
made blunt ended with T4 DNA polymerase and digested with
ClaI. The product (with a staggered 59 end and a blunt 39 end)
was ligated into ClaI- and SmaI-digested pBluescript KS2.
ORF-2 was expressed in vitro in a coupled transcription-trans-
lation system (Promega Corp., Madison, Wis.), and products
were metabolically labeled with [35S]methionine. Immunopre-
cipitations were performed as we previously described for as-
trovirus capsid proteins (14).
The selected hybridomas which produced antibodies reac-
tive with both stool-derived Norwalk virus and rNV capsid
protein were designated 1C9 and 1D8. No hybridomas were
found which reacted only with stool-derived virus or only with
rNV. The antibody isotype was immunoglobulin G1 for both
antibodies. The antibodies appeared to be directed against
different epitopes on the basis of blocking ELISA tests and the
finding that a mixture of the two gave higher ELISA values
than either one tested singly. This was confirmed by the finding
that only monoclonal antibody 1D8 reacted in an ELISA with
a synthetic peptide to the N terminus of the capsid (data not
shown). On the basis of these findings, a mixture of the two
antibodies was used both for coating plates and as detector
antibodies. To determine the sensitivity of the monoclonal
antibody ELISA relative to that of our previously developed
polyclonal ELISA, a stool sample from a volunteer was diluted
in PBS and tested by both immunoassays. The results are
shown in Fig. 1. The monoclonal antibody ELISA showed
greater reactivity (higher A492 values) and a twofold-higher
sensitivity in detecting Norwalk virus in a diluted stool speci-
men than the polyclonal antibody ELISA. Both of the ELISAs
are of the direct type. The detection limit for the monoclonal
antibody ELISA, as determined by end point titration of rNV
capsid antigen, was 0.05 ng per microwell, or 1 ng/ml (data not
shown).
The specificity of the monoclonal antibody ELISA for Nor-
walk virus was examined by ELISA tests with representative
types of gastroenteritis viruses in stool samples. The results,
FIG. 1. Titration of Norwalk virus antigen in a stool specimen from a vol-
unteer by monoclonal antibody ELISA (closed circles) and polyclonal antibody
ELISA (open circles). Points above the dashed line represent positive values for
the immunoassays.
TABLE 1. Specificity of the monoclonal antibody ELISA
for detecting Norwalk virus in stools
Patient group No. ofpatients
No. ELISA
positive
Volunteers inoculated with:
Norwalk virusa 15 15
Hawaii virus 9 0
Patients with:
Rotavirus infection 20 0
Astrovirus infection 7 0
Enteric adenovirus infection 7 0
United Kingdom calicivirus infection 5 0
Snow Mountain virus infection 1 0
‘‘Small round’’ virus infection 9 0
Diarrhea of unknown etiology 30 0
No diarrhea 25 0
a Stools previously found to contain Norwalk virus by a polyclonal ELISA (9).
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presented in Table 1, indicate that antibody reactivity did not
occur with normal stool samples or with samples containing
viruses other than Norwalk virus. All 15 Norwalk virus samples
tested which were previously found to be positive in a poly-
clonal antibody ELISA were also positive in the monoclonal
antibody ELISA.
The results of the immunoprecipitation studies are given in
Fig. 2. A predominant 58-kDa band, indicative of Norwalk
virus protein (12), was seen in crude lysates. Norwalk virus-
specific proteins were immunoprecipitated with monoclonal
antibodies 1D8 (Fig. 2B, lanes 1 and 2) and 1C9 (Fig. 2B, lanes
3 and 4). The predominant product seen in lanes 1 to 4 of Fig.
2B is a 58-kDa protein. An astrovirus-specific monoclonal an-
tibody (8E7) failed to immunoprecipitate any Norwalk virus
ORF-2 translation products (Fig. 2B, lanes 5 and 6). Con-
versely, Norwalk virus-specific monoclonal antibodies 1D8 and
1C9 did not immunoprecipitate any astrovirus capsid proteins
(Fig. 2B, lanes 7 and 8).
The reactivities of monoclonal antibodies with Norwalk vi-
rus in stools were determined primarily with stools obtained
from volunteers infected with a strain of Norwalk virus circu-
lating in 1968 (4). Because sera prepared against rNV capsid
protein appeared to be highly specific for the prototype Nor-
walk virus (5), we had expected that monoclonal antibodies
prepared against native virus would be more broadly reactive
than rNV-generated antibodies with Norwalk virus in naturally
occurring outbreaks. However, preliminary results with the few
stools we have from a documented Norwalk virus outbreak
have been inconclusive (eight stool samples positive by poly-
clonal antibody ELISA and five stool samples positive by
monoclonal antibody ELISA). Strains from additional Nor-
walk virus outbreaks, especially recent ones, will need to be
obtained and tested to determine the utility of the monoclonal
antibodies for the diagnosis of Norwalk virus gastroenteritis.
This work was supported by The Thrasher Research Fund and
Public Health Service Award AI 30448.
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FIG. 2. (A) In vitro transcription and translation of Norwalk virus ORF-2.
Untreated, radiolabeled translation products are shown. (B) Immunoprecipita-
tion of in vitro transcription-translation products. Immunoprecipitation of radio-
labeled Norwalk virus ORF-2 translation products with Norwalk virus-specific
monoclonal antibodies 1D8 (lane 1, 3 ml of reaction product immunoprecipi-
tated; lane 2, 15 ml) and 1C9 (lane 3, 3 ml; lane 4, 15 ml) was compared with
immunoprecipitation with astrovirus-specific monoclonal antibody 8E7 (lane 5, 3
ml; lane 6, 15 mL). Norwalk virus-specific monoclonal antibodies 1D8 (lane 7)
and 1C9 (lane 8) were also tested for reactivity with radiolabeled astrovirus
ORF-2 translation products (capsid). Numbers on the left and right are molec-
ular masses in kilodaltons.
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